DENZA Partners with DEVIALET on Car Audio System
23.3.2023 20:00:00 EET | Business Wire | Press release
On 22nd March 2023, the DENZA x DEVIALET Cooperation Kick-off Evening was held at the Bay Opera of Shenzhen. DENZA and DEVIALET jointly unveiled the DENZA N7, the world's first mass-produced model coming with the DEVIALET car audio system. This cooperation witnesses DENZA become the first brand to apply DEVIALET’s audio system and serves as a paradigm of international cooperation in the global automotive industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005522/en/
DENZA x DEVIALET Cooperation Kick-off Evening (Photo: Business Wire)
Zhao Changjiang, General Manager of DENZA, said: “High-quality music brings users enjoyment of life, and intelligent music cockpit is the standard element for the new luxury.”
Franck Lebouchard, CEO of DEVIALET, commented, “This is a collaboration between two market leaders with a mission to redefine sound experiences in mobility. Our partnership with DENZA marks a partnership concluded with a future leading player in the automotive market.”
Making the journey sound better, DENZA N7 comes with a new acoustic system that offers Hi-Fi sounds with cutting-edge technology and creates an intelligent music cockpit offering an immersive and pleasant sound experience. The tailor-made speaker in DENZA N7 can create an expansive yet precise sound field while preserving Hi-Fi precision. The SAM® (Speaker Active Matching) technology is employed to produce ultra-low frequencies down to 20Hz, creating a more powerful bass performance. The DEVIALET SPACE technology is used to deliver stereo sound effects and create an immersive ambiance. The SDVC (Speed Dependent Volume Control) technology unique to DEVIALET provides automatic volume adjustment depending on the speed of the vehicle.
DENZA N7 is where auto-design aesthetics meets with the art of acoustics. It features a look that inherits the DENZA family’s new design language, π-Motion. The golden ratio of 0.618 and the design of the long wheelbase combined with short front and rear suspensions render an elegant yet sporty body. The “Meteor Arrow” symbol running through the body presents a sharp-cut vibrant mark that is easy to identify. The front of N7 looks like a “bullet” pointing forward, creating a feeling of high speed. The waistlines are the perfect embodiment of the π-Motion design language as well. Fluent and graceful, the curved surface is seemingly poised to rein the wind. The one-piece through taillight strip extends to both sides, making it look as wide as a shooting brake. Zhao Changjiang said: “As a unique all-electric shooting brake, DENZA N7 brings perceived value that outstrips oil-fueled luxury SUVs and takes the exterior design of electric SUVs to the next level.”
Amid a new wave of internationalization, DENZA will align with more premium brands across multiple sectors, enrich the aesthetic meaning of luxury life, and bring an intelligent, accessible, and comfortable mobility experience to global users.
HD Photos: https://we.tl/t-nxUJMK6LWT
About DENZA
In 2010, Mercedes-Benz, as the "inventor of automobile", and BYD Auto, as the "leader of new energy vehicles", established DENZA, China's first joint venture brand of new energy vehicles with a high-end brand position to realize their common vision of the future of electric mobility by complementing each other's strengths. DENZA combines BYD's world-leading power batteries, electric motors, electronic control systems with Mercedes-Benz's intelligent manufacturing capability, vehicle tuning, and quality management systems.
About DEVIALET
DEVIALET is a French acoustical engineering company operating at the intersection of luxury and cutting-edge technology. DEVIALET’s mission is to elevate sound to its rightful place in people's lives by delivering uniquely meaningful audio experiences through iconic products.
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, the DM-i and DM-p hybrid technology, the e-Platform 3.0, and the CTB technology. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on EV shift and has remained top of new energy passenger vehicle sales in China for 9 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005522/en/
Contact information
Asia-Pacific: Mia Gu, pr@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: José Miranda, jose.miranda@byd.com tel: +56 9 96443906
Brazil: Adalberto Maluf, adalberto.maluf@byd.com tel: +19 3514 2554
Middle East and Africa: Nikki Li, tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
euNetworks launches new quantum-safe private connectivity service powered by Adtran’s encrypted optical transport technology27.5.2026 11:00:00 EEST | Press release
Adtran and euNetworks today announced their collaboration on the launch of a new quantum-safe private connectivity service, Quantum Shield. euNetworks has developed Quantum Shield using Adtran’s optical transport technology to augment its broader architecture, which is designed to deliver secure, scalable data center connectivity across euNetworks’ pan-European network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526610601/en/ Adtran’s encrypted optical transport technology is helping euNetworks deliver the highest levels of protection for sensitive data moving across Europe. The new offering is built for enterprises with stringent security, performance and customer-controlled encryption requirements. The deployment combines high-capacity dedicated infrastructure with real-time fiber monitoring and enhanced optical-layer visibility to safeguard critical traffic. By integrating advanced encryption with continuous monito
National Bank of Greece in Cyprus Goes Live With Smartstream’s Air to Consolidate Reconciliations27.5.2026 10:55:00 EEST | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that the National Bank of Greece (NBG) in Cyprus has successfully gone live with Air, the company’s AI-enabled reconciliation solution. The go-live marks a significant step forward in the bank’s operational efficiency, reducing daily manual processing effort and eliminating the complexity of working across multiple data formats. The bank has deployed Air’s Cash module, replacing both incumbent and consolidating four separate reconciliation systems for Instant, Cash, SEPA, and Nostro reconciliations, into a single, intelligent platform. Although transaction volumes were manageable, the fragmented landscape required significant daily manual effort to handle items individually across each system and to navigate multiple data formats. Following a market review, the bank committed to Smartstream’s Air, with self service model and AI-enabled automation being a distinct
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 10:20:00 EEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release
Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom